Preprint Watch 2026-05-22: 1 Clinical Failures Flagged for MDM2 | Claidex

Q: Why was this MDM2 preprint flagged?

1 prior Claidex failure claim matched the target-disease mechanism. The preprint reports genotype-dependent dysregulation of the MDM2-p53 axis modulating breast cancer susceptibility in Bangladeshi women, supporting the hypothesis that p53 pathway context determines MDM2 inhibitor response. This is consistent with brigimadlin-mdm2-class-shutdown: the MDM2 class continues to depend on TP53 wild-type tumor selection plus a still-unsolved patient stratification problem. The preprint reinforces the case that future MDM2 programs need genotype-anchored enrichment, not just MDM2-amplification cutoffs.

Claidex Preprint Watch

doi:10.64898/2026.05.18.726100

Preprint WatchMildMay 22nd, 2026

Genotype-Dependent Dysregulation of the MDM2-p53 Axis and Breast Cancer Susceptibility in Bangladeshi Women: A Cas-Control Study

Chowdhury, M. H.; Islam, F.; Khan, A. A.; Siddique, M. A.; Hasan, N. B.; Samrat, M. I.; Tanisha, M. H.; Tasnim, J.; Mahjabin, S.; Islam, M. N.; Haque, M. A.

Genotype-dependent dysregulation of the MDM2-p53 axis modulates breast cancer susceptibility, implicating patient genotype as a moderator of MDM2-targeted therapy response.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

The preprint reports genotype-dependent dysregulation of the MDM2-p53 axis modulating breast cancer susceptibility in Bangladeshi women, supporting the hypothesis that p53 pathway context determines MDM2 inhibitor response. This is consistent with brigimadlin-mdm2-class-shutdown: the MDM2 class continues to depend on TP53 wild-type tumor selection plus a still-unsolved patient stratification problem. The preprint reinforces the case that future MDM2 programs need genotype-anchored enrichment, not just MDM2-amplification cutoffs.

Abstract excerpt

Background: The MDM2-p53 signaling pathway plays a central role in tumor suppression, and genetic variants that disrupt this pathway may influence breast cancer (BC) susceptibility. However, data from South Asian populations, particularly Bangladesh, remain limited. Methods: A case-control study was conducted in Bangladeshi women, including BC patients and healthy controls (HCs). Genotyping of MDM2 polymorphisms was performed using PCR-based methods. Circulating MDM2 and p53 protein levels were measured using enzyme-linked immunosorbent assays (ELISA). Associations between genotype, protein le

Matching Claidex post-mortems

1 of 1 indexed

May 17, 2026Brigimadlin and Brightline-2: Boehringer closes a twenty-year MDM2-p53 betBrigimadlin (BI 907828)SponsorMRS 29

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.